Financing will fund phase 1b trials evaluating its lead candidate, THN391, for the treatment of Alzheimer’s Disease and diabetic macular edema (DME).

Kriya Therapeutics presented preclinical data on its gene therapy candidate for the treatment of geographic atrophy.

Ashvattha Therapeutics announced positive interim phase 2 results for migaldendranib for the treatment of AMD and DME.

SYL1801 is a treatment for neovascular macular degeneration administered via eye drops.

A recent analysis reveals a strong link between photoreceptor health and visual function in geographic atrophy, emphasizing the importance of EZ integrity.

Valeda met the primary end point in the US LIGHTSIDE III trial, improving the best corrected visual acuity in patients for 24 months of >5 letters or equivalent to 1 line improvement on the eye chart, according to the company.

A recent study reveals how geographic atrophy affects patients' vision and quality of life, highlighting their coping strategies and need for better resources.

New research reveals how low blood sugar can damage the retina in diabetes, highlighting potential treatments targeting specific proteins to prevent vision loss.

Palatin Technologies reveals groundbreaking preclinical results on melanocortin agonists, showcasing their potential to combat diabetic retinopathy and preserve vision.

Alfredo Sadun, MD, PhD, details a fascinating outcome from a gene therapy in development for Leber hereditary optic neuropathy.

The company shared results from the AAVB-081 clinical program and AAVB-039 preclinical program at ARVO.

The biomarkers are especially crucial for patients with lupus nephritis.

Post hoc analysis of GATHER1 and GATHER2 showed that reduced EZ-RPE central subfield thickness is a strong predictor of greater future vision loss.

Boehringer Ingelheim announced that the phase 2 clinical studies will investigate a potential first-in-class oral compound and a highly specific antibody fragment for geographic atrophy.

At Retina World Congress 2025, Dilsher S. Dhoot, MD, shares updates on the HELIOS trial and the potential future of tyrosine kinase inhibitors (TKIs).

Optigo Biotherapeutics presents promising preclinical data at ARVO.

Topline results from the Magnify phase 2 clinical trial of oral zervimesine show 28.6% slower geographic atrophy lesion growth compared with placebo.

Beacon Therapeutics reveals promising interim results for laru-zova, a gene therapy showing potential to improve vision in XLRP patients.

Machine learning algorithms enhance retinopathy of prematurity screening using smartphone images, expanding access in low-resource settings and easing pediatric ophthalmologist workloads.

Alkeus Pharmaceuticals reveals promising Phase 2 SAGA study results, showing gildeuretinol slows vision decline in geographic atrophy linked to AMD.

Pykus Therapeutics reveals promising results for PYK-2101, a retinal sealant that enhances recovery and improves patient experience in retinal detachment surgery.